How is bimodal neuromodulation applied to the tongue in an adult with chronic subjective tinnitus using the FDA‑cleared Lenire system?

Bimodal Neuromodulation with Lenire: Technical Application

Bimodal neuromodulation to the tongue using the FDA-cleared Lenire system combines electrical tongue stimulation with synchronized sound therapy delivered through headphones, where patients place a tongue electrode array in their mouth and use the device for up to 60 minutes daily over 12 weeks.

Device Components and Setup

The Lenire system consists of three key elements 1:

• Tongue electrode array: A specialized electrode placed on the tongue surface that delivers electrical stimulation
• Headphones: Standard audio headphones that deliver calibrated sound stimuli
• Control unit: A handheld device that synchronizes the timing between tongue stimulation and auditory input

Treatment Protocol

Initial Treatment Phase

Patients undergo a structured 12-week treatment regimen 2, 3:

• Daily usage: Up to 60 minutes per session
• Stimulation pattern: Electrical pulses delivered to the tongue are precisely timed with specific sound patterns (pure tones) delivered to the ears
• Follow-up schedule: Clinical assessments at 6 weeks and 12 weeks

Mechanism of Delivery

The bimodal approach works by 4:

• Tongue stimulation: Electrical pulses activate the trigeminal nerve (cranial nerve V), which provides somatosensory input
• Auditory stimulation: Sound therapy (pure tones without requiring background wideband noise) delivered simultaneously through headphones 5
• Temporal synchronization: The critical element is the precise timing between tongue and sound stimulation, which drives neuroplasticity in auditory brain regions

Parameter Adjustments

A key technical feature is adjusting stimulation parameters at 6 weeks to overcome treatment habituation effects 5. This parameter modification during the second 6-week period significantly enhances therapeutic outcomes and prevents the diminishing improvements observed when settings remain static.

Patient Selection Criteria

The device is FDA-approved and clinically effective specifically for adults with moderate or worse tinnitus severity (Tinnitus Handicap Inventory [THI] ≥ 38) 2, 1. Real-world evidence demonstrates:

• Responder rate: 81.8% to 91.5% achieve clinically significant improvement (≥7-point THI reduction) in patients with moderate or worse tinnitus 2, 3
• Mean improvement: 23.8 to 27.8-point reduction in THI scores after 12 weeks
• Ineffective in mild cases: Patients with slight or mild tinnitus show nearly zero change, making severity assessment critical before prescribing 2

Safety Profile

The treatment demonstrates excellent safety with 1, 4:

• No device-related serious adverse events reported across multiple trials
• High compliance rates (83.8%)
• 70.3% of participants reporting subjective benefit

Clinical Pitfalls to Avoid

Do not prescribe Lenire for patients with slight or mild tinnitus (THI < 38), as real-world data shows no therapeutic benefit in this population 2. This represents a critical patient selection error that wastes resources and creates false expectations.

The necessity of combining both modalities is absolute—sound therapy alone produces inferior results (43.2% responder rate) compared to bimodal treatment (58.6% responder rate) in the moderate-to-severe population 1.

Long-term Outcomes

Therapeutic improvements persist for 12 months post-treatment when appropriate parameter adjustments are made during the treatment period 4, 5, representing the first large-cohort demonstration of sustained tinnitus intervention effects.